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Summary 
HLA-A2-restricted, CD3 +,  CD8 + , ol/B + cytotoxic T  cell (CTL) clones were isolated  from 
peripheral blood (PBL) or tumor infiltrating lymphocytes (TIL) of two HLA-A2 + melanoma 
patients (9742 and 5810), to evaluate the possible recognition of autologous melanoma and of 
allogeneic HLA-A2-matched normal melanocytes.  These CTL clones lysed not only fresh and 
cultured autologous melanoma cells, but also allogeneic HLA-A2 +, but not HLA-A2-, normal 
melanocytes.  The lysis of autologous neoplastic cells and of melanocytes could be inhibited by 
an anti-HLA-A2 monoclonal antibody (mAb). Lysis of the normal melanocytes was not dependent 
on the presence of human or fetal calf serum in the culture medium. HLA-A2-restricted CTL 
clones recognized not only proliferating melanocytes cultured in complete melanocyte medium, 
but also melanocytes made quiescent by culture for up to 6 d in a basal medium devoid of exogenous 
factors such as phorbol ester (O-tetradecanoyl phorbol 13-acetate [TPA]), epidermal growth factor, 
insulin, and pituitary extracts.  Analysis of specificity of four CTL clones (A75, A83, A94, and 
119) from patient 9742,  performed on a panel of 39 targets,  indicated that the three HLA- 
A2-restricted CTL (A75, A83, and A94) lysed all but one of nine allogeneic melanomas expressing 
the HLA-A2 molecule with no reactivity on nine HLA-A2- allogeneic melanomas. Only a few 
instances of borderline reactivity were seen by the same effectors on 21 targets of nonmelanocyte 
lineage,  including 12 carcinomas  of different histology, four Epstein-Barr virus-transformed B 
cells (lymphoblastoid cell lines  [LCL]),  including the autologous LCL, four lines  of normal 
fibroblasts,  and normal kidney cells. Lack of reactivity on allogeneic targets of nonmelanocyte 
lineage occurred in spite of expression  of HLA-A2 on 14 of these targets as determined by 
conventional tissue typing and cytofluorimetric analysis with four different anti-HLA-A2 mAb. 
These data indicate that tissue-related  antigens can be expressed on normal and neoplastic cells 
of the melanocyte lineage and can be recognized in association with HLA-A2 by CTL clones 
from melanoma patients. 
T 
he clonal analysis ofT cell-mediated response to human 
melanoma has indicated that some of the CTL clones 
from a number of patients can recognize tumor-associated 
antigens (TAA) 1 by a TCR-dependent and HLA-restricted 
mechanism (1). These CTL clones are thought to recognize 
TAA by the same mechanism that controls T  cell recogni- 
tion of conventional antigens, i.e., as peptides associated with 
1 Abbreviations used in this paper: ADAbp, adenosine deaminase binding 
protein; EGF, epidermal growth factor; ICAM-1, intercellular adhesion 
molecule; LCL, lymphoblastoid cell line; MCM, melanocyte complete 
medium; MLTC, mixed lymphocyte tumor culture; mCSP, melanoma 
chondroitin sulfate proteoglycan;  PHS, pooled  human serum; TAA, tumor- 
associated antigen; TIL, tumor-infiltrating lymphocyte. 
one of the HLA molecules expressed by the patient's neo- 
plastic cells (2). 
At least two hypotheses have been put forward to explain 
the genesis of the antigenic peptides seen as TAA by autolo- 
gous CTL clones. The first one is that antigenic peptides may 
originate from the intracellular processing of proteins whose 
genes should be expressed in neoplastic but not in normal 
cells. Molecular evidence in agreement with this mechanism 
has been recently obtained for an antigen recognized on mela- 
noma cells in association with HLA-A1 (3). A second possi- 
bility is that the generation of antigenic peptides in human 
tumors is dependent on the presence in the neoplastic cells 
of gene mutations affecting the structure of proteins expressed 
also in normal cells. Evidence consistent with this mecha- 
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tides corresponding to regions of R.AS oncogenes altered by 
point mutations (4). Both models of TAA generation share 
the assumption that antigens seen by human T lymphocytes 
on neoplastic cells should not be expressed on the normal 
cells of the same tissue (5). However, this hypothesis could 
not be verified in melanoma because of the lack of normal 
cells sharing the appropriate HLA-restricting element and the 
same histological origin with the neoplastic cells recognized 
by tumor-specific and HLA-restricted CTL clones. 
In this study, CTL clones from melanoma patients were 
tested for cytotoxic activity not only on autologous tumor 
but also on allogeneic HLA-A2-matched melanocytes. The 
results indicate that among the PBL or tumor-infiltrating lym- 
phocytes (TIL) of two HLA-A2 + melanoma patients, one 
with primary and the other with metastatic disease, it is pos- 
sible  to find some CD3 +,  CD8 +,  or~f3 + CTL clones that 
lyse autologous and allogeneic HLA-A2 +  melanoma cells 
and allogeneic HLA-A2 + normal melanocytes. These data 
show for the first time that tissue-related antigens can be ex- 
pressed on normal and transformed cells of the melanocyte 
lineage and be recognized in an HLA-restricted fashion by 
patients' T  lymphocytes. 
Materials and Methods 
Normal and Neoplastic Cells.  All melanoma cells used in this 
study were isolated from primary and metastatic lesions obtained 
from surgical specimens of patients admitted for surgery to the 
Istituto Nazionale Tumori in Milan. All tumor and normal cells 
were kept in culture with 10% FCS-RPMI-1640. Melanoma cells 
to be used as stimulators for mixed lymphocyte tumor cultures 
(MLTC) or for T call clones and all targets to be used in cytotoxic 
assays were instead cultured in 10% pooled human serum (PHS)- 
RPMI-1640.  Normal human  melanocytes (FM 216/A, FM713, 
FM727, and FM741) isolated from neonatal foreskin were cultured 
with a chemically defined medium as described (6). Briefly, the 
melanocyte complete medium (MCM) consisted of a base medium 
with four parts of MCDB 153 medium supplemented with 2 mM 
Ca  2+ and one part of Leibovitz's L15 medium, 5 ng/ml epidermal 
growth factor (EGF), 40/~g/ml bovine pituitary extract, 5/~g/ml 
insulin,  10  ng/ml  phorbol  ester  (TPA)  (all from  Sigma Im- 
munochemicals, St. Louis, MO), and 2% FCS (ICN Biomedicals, 
Hyland, CA) or 2% PHS. For some experiments  MCM was replaced 
with a basal medium lacking EGF, pituitary extract, insulin, and 
TPA. Normal and neoplastic cells were also checked by electron 
microscopy for the absence of mycoplasma contamination and for 
the presence of  premelanosomes in cells of the melanocyte lineage. 
EBV-transformed lymphoblastoid cell line [LCL] from four mela- 
noma patients (9742, 10538, 1811, and 4405) were produced by 
infection of PBL with supernatant from the EBV producer line 
B95.8 as described (7). 
T Cell Clones.  PBL and TIL were isolated as described (7) from 
melanoma patients 9742 (HLA-A2, -A24; -B13, -B18; -Cw6, -Cw7; 
-DR7, -DK11; and -DQ4) and 5810 (HLA-A2, -A24; -B18, -B63; 
-Cw7;  -DR6,  -DR11;  and  -DQ1,  -DQ7).  The  lymphocytes 
(106/ml) were cultured  for 3-4 wk with autologous  irradiated 
(10,000 tad) metastatic (patient 9742) or primary (patient 5810) 
melanoma cells first in 24-well plates (model 3424; Costar Corp., 
Cambridge, MA) and then in 25 cm  2 flasks (model 25100B; Bibby 
Scientific Products Ltd., Stone, UK) at a lymphocyte/tumor ratio 
of 5:1 in 10% PHS-RPMI-1640 in the presence of 50 U/ml of rib2 
(EuroCetus, Amsterdam, The Netherlands). The cultures were re- 
stimulated weekly with autologous tumor cells. At the end of 4 wk 
of  culture, cells were cloned by limiting dilution. Cloning was per- 
formed as described (7) in 96 round-bottomed well plates (model 
3799; Costar Corp.) with 10% PHS-RPMI-1640  supplemented  with 
50 U/ml of rlL-2 in the presence of irradiated autologous tumor 
cells (5  x  103/well) and  allogeneic pooled lymphocytes (5  x 
104/well, irradiated at 3,000 tad) from at least three donors as a 
source of feeder cells. Cloning was performed at 5, 1, 0.5, and 0.25 
cells/well. The plates were restimulated with autologous tumor 
cells and feeder cells after 1 wk of culture and screened at day 14 
for the presence of growing  clones. On the basis of the cloning 
efficiency,  which ranged between 0.5 and 17%, a frequency  ofclono- 
genic precursors was evaluated and used to determine the proba- 
bility of clonality of each clone by Poisson statistics as described 
by Taswell et al. (8). Only clones having ap value for true clonality 
of at least 0.95 were used in this study. True clonality of the effectors 
used in this study was confirmed by analysis of TCR-Vot and -V/3 
expressi'on in each clone, performed by RT-PCK with primers 
specific for all known members of the Vc~ and V/$ gene families. 
This analysis revealed that only one Vcr and one VB mRNA was 
exressed  by each clone (Senti, M., S. Salvi, C. Castelli, C. Maccalli, 
A.  Mazzocchi, R.  Mortarini,  M. Herlyn, G. Permiani, and A. 
Anichini, manuscript in preparation). 156 clones from patient 9742 
and 223 clones from patient 5810, selected on the basis of a p value 
for clonality >0.95, were screened for cytotoxicity on the autolo- 
gous melanoma and, at the same time, for inhibition of tumor lysis 
by anti-CD3 and anti-HLA class I antibodies. 63 clones from pa- 
tient 9742 (30 from TIL and 33 from PBL) and 28 clones from 
patient  5810 (12 clones from TIL and 16 from PBL) expressed 
significant cytotoxic activity on the autologous tumor,  and were 
inhibited by both anti-CD3 and anti-HLA class I mAb. CTL clones 
from patient 9742 were also obtained by direct cloning at 0.5 and 
0.25 cells/well of fresh PBL in the presence of allogeneic irradiated 
PBL, 50 U/ml of rll.,2,  and 1% PHA (Difco Laboratories, Inc., 
Detroit, MI). 207 clones with a p value for clonality of 0.96 were 
screened for cytotoxic activity and 21 were cytotoxic on the auto- 
logous tumor and inhibited by anti-HLA class I mAb. All CTL 
clones used in this study expressed a CD3 +, CD4-, CD8 ~, c~/B  + 
phenotype  as  assessed,  respectively,  with  antibodies OKT3 
(CRL8001; American  Type Culture Collection [ATCC], Rockville, 
MD), OKT4 (CRL8002; ATCC), OKT8 (CRL8014; ATCC) and 
by the anti-TCK-c~/~ mAb  WT31  (Becton Dickinson  & Co., 
Mountain  View, CA). 
Cytotoxicity Assay.  Target cells (106) were labeled for 90 rain 
at 37~  with 100 #Ci of Na2SlCrO4 (Amersham International, 
Amersham, Bucks, UK). After three washings with cold medium, 
the  targets  were adjusted to 10Uml in  10~  PHS-RPMI-1640. 
Effectors were resuspended at various concentrations to give final 
effector/target ratios ranging between 50:1 and 5:1. Effectors and 
targets were then seeded in 0.1 ml aliquots in v-bottomed 96-well 
plates (model 3596; Costar Corp.), centrifuged at 60 g for 5 min 
and incubated at 37~  5% CO2 for 4 h. At the end of the incu- 
bation  time, 0.125 ml of supernatant was collected, mixed with 
0.7 ml of  cocktail (Ready-Solve  HP 158726; Beckman Instruments, 
Geneva, Switzerland) in Micronic PPN tubes (Flow Laboratories, 
Settimo Milanese, Italy) and counted  in a beta counter (model 
LS1801; Beckman Instruments).  Results (in cpm) were expressed 
as follows: percent lysis = experimental release -  spontaneous re- 
lease/maximum release -  spontaneous release, where spontaneous 
release was assessed by incubating  target cells in the absence of 
effectors and maximum release was determined in the presence of 
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of lysis by mAb to CD3, HLA-A2, HLA class I, and HLA-DR 
antigens was performed by preincubating the effectors  or the targets 
with different purified mAb in 0.1 ml for 45 min at 37~  Then 
effectors or targets were added in 0.1 ml aliquots and the cytotox- 
icity assay was carried out as described above. The assays were per- 
formed at the final concentration  of 1 #g/ml for each mAb. 
Proliferation Assay.  Melanocytes were incubated for 48-72 h in 
0.2 ml of MCM or in a basal medium without EGF, pituitary ex- 
tracts, insulin, and TPA in flat-bottomed 96-well plates (model 3595; 
Costar Corp.) at the initial concentration  of 2  x  104 cells/well. 
The cultures were pulsed with 1 #Ci [3H]thymidine/well (sp act. 
6.7 Ci/mmol)  (Amersham International)  during  the last 8 h of 
cultures. Each sample was then harvested, absorbed onto nitrocel- 
lulose paper, and washed using a harvester (Titertek; Flow Labora- 
tories). The nitrocellulose filters were dried and counted after liquid 
scintillation  in a beta counter (model LS1801; Beckman Instru- 
ments). The proliferation assay  was performed in six replicate wells. 
mAb andPhenotypic  Analysis.  Phenotype of CTL clones, mela- 
nocytes, and  all tumor cells was performed  by indirect  immu- 
nofluorescence followed by cytofluorimetric analysis on a FACScan  | 
cytofluorimeter (Becton Dickinson & Co.) as previously described 
(9). The following mAb were used: W6/32 (10), anti-HLA class I; 
CRll.351 (11), BB7.2 (12), PA2.1 (13) and MA2.1 (14), anti-HLA- 
A2; R24 (15), antiganglioside GD3; 528 (16), anti-EGF-receptor; 
17Fll (17), anti-c-kit  protein; C350 (18), anti-gp180; B5.2 (18), anti- 
melanoma  chondroitin  sulfate proteoglycan  (mCSP);  $27  (19), 
anti-adenosine deaminase binding protein (ADAbp); ME20.4 (6), 
anti-nerve growth factor (NGF) receptor;  ME9-61  (6), anti-p97 
melanotransferrin; TA99 (20), anti-gp75 tyrosinase-related glyco- 
protein; TR66 (21), anti-CD3; 84H10 (22), anti-intercellular adhe- 
sion molecule 1 (ICAM-1);  and TS2/9 (23) anti-LFA-3. 
Results 
Lysis of Autologous HLA-A2 § Tumor and Anogeneic HLA- 
A2 § Metanowtes by CTL Clones from TIL and PBL of Mela- 
noma Patients.  Table 1 shows the biological characterization 
of the human newborn foreskin melanocytes used in this study. 
All melanocytes are pigmented cells;  have a bipolar/spindle 
morphology;  grow  as  anchorage-dependent  cells;  are not 
tumorigenic when injected into nude mice;  have a normal 
diploid karyotype, undergo senescence after a limited number 
of passages in vitro; and three out of four depended on the 
presence of phorbol ester for growth.  By cytofluorimetric 
analysis,  all these cells express HLA class  I antigens  as de- 
tected by the antibody w6/32 (10). In addition, melanocytes 
FM741 and FM727 are positive for HLA-A2 after staining 
with the anti-HLA-A2 antibody CRll.351 (11), whereas the 
melanocytes FM216/A and FM713 do not react with the mAb. 
The expression of HLA-A2 on melanocytes FM741 and FM727 
and the lack of this determinant  on FM713 and FM216/A 
was confirmed by conventional HLA tissue typing and by 
immunofluorescence with three additional anti-HLA-A2 mAb, 
MA2.1 (13), BB7.2 (12),  and PA2.1  (14) (data not shown). 
All other phenotypic markers  were similarly expressed on 
the four melanocyte cultures. In fact, as described for prolifer- 
ating melanocytes in vitro (6, 24), all melanocytes expressed 
the ganglioside GD3 (15) and a low but significant amount 
of the  adhesion  molecule  ICAM-1  (22).  All  melanocytes 
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reacted significantly with  an anti-LFA-3  antibody (23).  In 
addition, all melanocytes were weakly positive for the EGF 
receptor (16) and for mCSP, which are considered early markers 
of melanocyte differentiation  (18),  but were strongly posi- 
tive for gp180, recognized by antibody C350, a late marker 
of melanocyte differentiation  (18).  Also,  all cells expressed 
the tyrosinase-related gp75 marker (20), the NGF receptor 
(6), and p97, melanotransferrin  (6). Furthermore,  all mela- 
nocytes expressed the product of the c-kit gene (17) and ADAbp 
(19), two antigens that are expressed on normal melanocytes 
but that  are lost on melanoma cell lines  (19,  25). 
These melanocytes were used as targets to screen CTL clones 
from two HLA-A2 + melanoma patients.  CTL clones with 
cytolytic activity on melanocytes were isolated from a larger 
panel of 112 CTL clones initially selected for: (a) cytotoxic 
activity on the autologous tumor; and (b) blocking of mela- 
noma lysis by anti-CD3  and anti-HLA class I mAb.  Table 
2 shows that some of these effectors, sharing a CD3 + CD8 + 
WT31 + phenotype and isolated from PBL or TIL of two 
HLA-A2 + melanoma patients,  could lyse not only the au- 
tologous tumor but also some allogeneic melanocytes. Lysis 
of autologous tumor by CTL clones A75, A81, A83, A94, 
A103, A37, A54, and 211, but not  119, could be inhibited 
by preincubating melanoma cells with the anti-HLA-A2 mAb 
CRll.351.  This is in agreement with the known blocking 
activity of this mAb. In fact, a previous report from this lab- 
oratory has shown that  antibody CKll.351  can block the 
lysis  of  any  HLA-A2 +  target  by  an  alloreactive  HLA- 
A2-specific CTL  clone  (26).  In  addition,  only allogeneic 
melanocytes expressing HLA-A2 (FM741 and FM727) were 
recognized by the same effectors, suggesting an HLA-A2- 
restricted recognition  of antigens  expressed on autologous 
melanoma  and  allogeneic  normal  melanocytes.  Clone  119 
represents an example of the many CTL clones isolated from 
the two patients that did not recognize allogeneic HLA-A2 + 
melanocytes and were not blocked by mAb CRll.351 in the 
lysis on the autologous tumor,  thus indicating  that  clones 
such as  119 are not  HLA-A2 restricted. 
Cytolytic Activity on Normal Melanocytes by CTL Clones Is 
HLA-A2 Restricted and Not Dependent on the Proliferative Status 
of the Target Cells or on Composition of the Melanocyte Culture 
Medium.  Table 3 shows that  the lysis of HLA-A2 + mela- 
nocytes by two different CTL clones (CTL A83 and CTL 
A94) from patient 9742 could be inhibited by preincubating 
the targets with the anti-HLA-A2 mAb CRll.351, indicating 
that the recognition of these cells occurs by the same mecha- 
nism  seen for the lysis of the autologous melanoma.  Also, 
lysis of melanocytes was not due to the presence of bovine 
or human serum in the culture medium.  In fact, HLA-A2 + 
melanocytes were equally lysed after culture for at least 2 wk 
in the presence of either 2% FCS or 2% PHS, whereas one 
HLA-A2-  melanocyte was not recognized after culture in 
the presence of either  FCS or PHS. 
We next tested the possibility that the proliferative status 
of the melanocytes might influence antigen recognition by 
CTL clones. In fact, and in agreement with the data of Table 
1, it is known that proliferating human melanocytes in cul- 
ture can undergo phenotypic changes characterized  by de novo Tabh  1.  Characterization  of Human Foreskin Melanocytes 
Characteristic 
Melanocytes 
FM741  FM727  FM713  FM216/A 
Morphology 
Pigmentation  (+  to  +  +  +  +) 
Karyotype 
Growth  in  soft  agar 
(%  colony forming el:hciency) 
Tumorigenicity 
(No.  of mice with  tumors/total  injected) 
Dependence on phorbol ester 
Maximum  No.  of passages 
before senescence 
Bipolar  Bi- to  tripolar  Tripolar  Spindle 
+  ++  +++  ++ 
Diploid  ND  Diploid  Diploid 
<0.001%  <0.001%  <0.001%  <0.001% 
0/4  ND  ND  0/4 
Yes  Yes  Yes  No 
31  21  39  29 
Phenotype  mA b 
HLA-I*  w6/32  ++++1  ++++  ++++  ++++ 
HLA-A2  CRll.351  +  +  +  +  +  +  +  +  -  - 
ICAM-1  84H10  +  +  +  + 
LFA-3  TS2/9  +  +  +  +  +  +  +  + 
GD3  Ganglioside  R24  +  +  +  +  +  +  +  +  +  +  +  + 
EGF  Receptor  528  +  +  +  + 
gp180  C350  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
mCSP  B5.2  +  +  +  + 
c-Kit  protein  17Fll  +  +  +  +  +  +  +  + 
gp75  (Tyrosinase-related)  TA99  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NGF-Receptor  ME20.4  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
p97  Melanotransferrin  ME9-61  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
ADAbp  $27  +  +  +  +  +  +  +  + 
All melanocytes  (FM741,  FM727,  FM713,  and FM216/A) grow in liquid culture as adherent  cells but do not grow in semisolid medium (0.35% 
agarose).  Tumorigenicity was tested by subcutaneous  injection of 106 cells into nude mice. 
* Phenotype of proliferating  melanocytes  kept in MCM was  evaluated  by indirect  immunofluorescence  with the indicated  antibodies.  Expression 
of gp75 was measured  on permeabilized  cells. Expression  of HLA-A2 on melanocytes  was tested with identical results  also with antibodies  PA2.1 
(13),  BB7.2  (12),  and MA2.1  (14). 
* Results are expressed as follows:  -, <10% positive cells;  +, 11-25% positive cells;  + +, 26-50% positive cells;  +  + +, 51-80% positive cells; 
+ + + +,  >80%  positive  cells. 
expression of serologicaUy  defined antigens normally found 
on melanoma but not on resting melanocytes (6, 24) such 
as  the  ganglioside GD3  and  ICAM-1.  However,  antigenic 
recognition of melanocytes by CTL dones was seen not only 
on proliferating cells, as when using target melanocytes cul- 
tured in MCM, but also on growth-arrested cells. In fact (Table 
3), HLA-A2 + quiescent melanocytes, obtained by culture for 
up  to 6  d  in a basal medium  devoid of all main exogenous 
factors (EGF, insulin, TPA, and pituitary extracts), were still 
recognized, even though with less efhciency, by CTL clones 
A83 and A94. However, the quiescent melanocytes were rec- 
ognized with lower efficiency also by LAK cells, the positive 
control of lysability. A possible reason for the reduced lysa- 
bility of resting melanocytes was found, through FACS  |  anal- 
ysis, by comparing the phenotype of proliferating and quies- 
cent cells. In fact, HLA class I antigens and HLA-A2 molecules 
were expressed at similar levels, whereas ICAM-1 was absent 
on resting cells  (data  not  shown). 
In addition, as seen for proliferating melanocytes, the lysa- 
bility of growth-arrested melanocytes was not influenced by 
presence of FCS or of PHS in the basal medium (data  not 
shown). Test of lysis with quiescent melanocytes maintained 
in basal medium for more than 6 d could not be performed 
because substantial cell death ensued after  this time point. 
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Lysis of autologous  melanoma 
Lysis of melanocytes 
FM216/A  FM713  FM727  FM741 
Patient  Effector  - mAb*  + mAb*  HLA-A2-  HLA-A2-  HLA-A2 §  HLA-A2 * 
9742 
5810 
PBL A75"  45s  911  0  0  31  22 
PBL A81  33  6  II  1  0  40  27 
PBL A83  65  21  It  0  4  39  30 
PBL A94  45  7  II  0  0  30  25 
PBL A103  28  111  0  0  2_55  14 
PBL 119  32  31  0  0  ND  1 
TIL A37  20  0 II  0  2  20  8 
TIL A54  24  0 ~1  1  2  33  16 
LAK  5_00  50  22  49  34  41 
PBL 211  18  0  II  0  0  26  10 
LAK  54  51  43  3A  28  31 
Lysis of autologous tumor (Me9742 or Me5810) and of allogeneic melanocytes  by CTL clones isolated from TIL or PBL of two melanoma patients 
was tested in a 4-h 5:Cr-release assay at the E/T ratio of 10:1. 
* CTL clones A75, A81, A83, A94, A103, 211 (isolated  from PBL), A37, and A54 (isolated  from TIL)  were obtained  after MLTC, whereas clone 
119 (isolated  from  PBL)  was obtained  by direct cloning  of fresh PBL in the presence  of 1% PHA. LAK cells were produced by culturing allogeneic 
PBL from a normal donor in the presence of 100 U/ml of rlL-2 for 1 wk. 
* Lysis of Me9742 and of Me5810 was tested with or without preincubating target cells with 1/~g/ml of the anti-HLA-A2 mAb CRll.351. 
S  Results expressed  as percent lysis. Underlined values represent significant values of lysis in comparison to the spontaneous release of each target - 
(SNK test p  -  0.01). 
tl Lysis of the target in the presence of mAb is significantly  different from lysis of the same target in the absence of mAb (SNK test, p  =  0.01). 
These data indicate that some antimelanoma CTL clones can 
react in an HLA-A2-dependent fashion to antigens expressed 
on proliferating and resting normal melanocytes. 
HLA-A2-restricted CTL Clones Lyse only HLA-A2 + Cells 
of the Melanocyte Lineage.  Table  4  shows  the  analysis  of 
specificity of three of the CTL clones from patient 9742 that 
lysed allogeneic HLA-A2 +  melanocytes (CTL A75,  CTL 
A83, and CTL A94) and of one CTL clone that did not kill 
these cells (CTL 119). As expected, on the basis of the selec- 
tion criteria adopted to isolate these clones, the lysis of autol- 
ogous tumor by all clones, but not by control LAK cells, 
was inhibited by two different anti-CD3 antibodies (OKT3 
and TR66) and by the anti-HLA class I mAb W6/32, but 
not by a control anti-HLA-DR mAb (L243) (27). CTL clones 
A75, A83, and A94 lysed all but one (Me4855) allogeneic 
melanomas expressing HLA-A2, but did not lyse the mela- 
nomas lacking this determinant, with the exception of a bor- 
derline reactivity by CTL clone A83 on melanomas 665/1 
and 4405. In addition, all four CTL clones failed to lyse the 
two HLA-A2 + LCL obtained by EBV infection of PBL from 
the HLA-A2 + patients 9742 (i.e., the autologous LCL) and 
10538.  All clones expressed borderline or no lytic activity 
on most of the allogeneic and normal cells of nonmelanocyte 
lineage, including 12 carcinomas of different histology, four 
lines of normal fibroblasts (F1338/1, F8536, F9203, F3046), 
and normal kidney ceils (Re458), even though HLA-A2 was 
expressed on 10 of these targets. Only one of the HLA-A2- 
restricted clones (A83) expressed a low but signifcant lytic 
activity on two HLA-A2 + fibroblasts (F1338/1 and F3046) 
and on one HLA-A2 + renal carcinoma (Reca458). 
The specificity of CTL clone 119 indicated that additional 
antigenic determinants, seen in association with HLA class 
I alleles which are different from HLA-A2, must be expressed 
on melanoma 9742. In fact, Table 4 shows that the cytotoxic 
activity of this clone on the autologous tumor is inhibited 
by antibodies to CD3 and to HLA class I antigens, indicating 
that this clone acts by a TCR-dependent and HLA dass I- 
restricted mechanism. Lack of  lysis of allogeneic targets, either 
in the melanocyte or in the nonmelanocyte lineage by CTL 
119 might be dependent on the presence of unique antigens 
seen only on Me9742 cells or on the lack of appropriate re- 
striction element on the allogeneic targets. The latter possi- 
bility is in agreement with the observation made by com- 
paring the HLA phenotype of the tumor 9742 with that of 
the allogeneic targets used for the specificity assay (data not 
shown).  This comparison revealed  the  existence of a  few 
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Percent lysis 
Anti-HLA-A2 
Melanocytes  Medium  mAb  CTL A83  CTL A94  LAK 
HLA-A2 § 
FM727  MCM  +  2%  PHS*  -~  49  s  39  58 
FM727  MCM  +  2%  PHS  +  1211  0 II  55 
FM727  MCM  +  2%  FCS  -  47  33  53 
FM727  Basal  +  2%  FCS  (72  h)  -  28  21  30 
FM727  Basal  +  2%  FCS  (144  h)  -  26  200  37 
FM741  MCM  +  2%  PHS  -  44  39  56 
FM741  MCM  +  2%  PHS  +  411  0 II  55 
FM741  MCM  +  2%  FCS  -  3_77  26  55 
FM741  Basal  +  2%  FCS  (72  h)  -  19  17  25 
FM741  Basal  +  2%  FCS  (144  h)  -  26  20  39 
HLA-A2- 
FM713  MCM  +  2%  PHS  -  0  0  38 
MCM  +  2%  FCS  -  0  0  36 
Lysis of melanocytes was tested in a 4-h slCr-release assay at the E/T ratio of 10:1. CTL A83 and A94 derived from MLTC of PBL from Patient 
9742. LAK cells were produced as described in the legend to Table 2. 
* Melanocytes were cultured in MCM as described in Materials and Methods in the presence of either 2% FCS or 2% PHS for at least 2 wk before 
using them in the cytolytic assay. The basal medium consisted of MCDB  153 plus L15 without EGF, insulin, pituitary extract,  and TPA.  After 
48 h  of culture in MCM the  [3H]thymidine incorporation by FM727 and FM741 was 6,603  +_ 522 cpm and 5,887  _+ 634 cpm,  respectively. 
[3H]Thymidine incorporation of the same cells after 48 h of culture in basal medium was 467  _+ 201 cpm (FM727) and 672  _+ 310 cpm (FM741). 
pH]Thymidine incorporation of FM727 and FM741 became negligible after 72 h of culture in basal medium and the cells began to die progressively 
after 144 h. 
* Lysis of melanocytes was inhibited by preincubating the targets with 1 #g/ml of the mAb CRll.351. 
S Results expressed as percent lysis. Underlined values represent significant values of cytotoxicity in comparison to the spontaneous release of each 
target  (SNK test, p  =  0.01). 
II Lysis in the presence of the antibody is significantly different from lysis in the absence of antibody (SNK test, p  =  0.01). 
matches for HLA-A2, -A24, -B18, -Cw6, and -Cw7, but no 
matches were available for the HLA class I allele B13 expressed 
by 9742  cells. 
Finally, all clones shown in Table 4 lysed not only the cul- 
tured tumor, but also the fresh, uncultured melanoma, even 
though to a lesser extent than the cultured tumor. However, 
the fresh tumor was recognized with lower efficiency than 
the cultured  tumor also by LAK cells used as positive con- 
trol of target lysability. By cytofluorimetric analysis, the fresh 
tumor expressed,  in comparison with  the cultured  tumor, 
lower amounts  of HLA class  I,  HLA-A2  antigens,  and  of 
two main adhesion molecules, ICAM-1 and LFA-3 (data not 
shown). The reduced expression of these critical determinants 
of the effector-target interaction may explain the reduced lys- 
ability of the  fresh tumor. 
Taken together, the results of the specificity analysis indi- 
cate that CTL clones such as A75, A83, and A94 recognize, 
in a TCR-dependent and HLA class I-restricted fashion, an- 
tigenic determinants preferentially expressed on normal and 
neoplastic cells of the melanocyte lineage and seen in associa- 
tion  with  HLA-A2. 
Discussion 
The  results  of this  study indicate  that  some HLA class 
I-restricted CTL clones from melanoma patients can recognize 
HLA-A2 § normal and neoplastic cells of the melanocyte lin- 
eage.  This  suggests  that  at least  some of the  antigens  de- 
tected by T  lymphocytes from melanoma patients might be 
related to the expression of tissue-related genes. A possibility 
is that peptides seen by the CTL clones in association with 
HLA-A2 derive from the processing of proteins encoded by 
genes preferentially expressed in cells of the melanocyte lin- 
eage. Alternatively, one should hypothesize the existence of 
tissue-specific differences in the mechanisms of antigen pro- 
cessing. These differences might lead, in different cell types, 
to the production  and assembly with HLA-A2 of different 
peptides not necessarily originating from tissue-specific pro- 
teins. Both these hypotheses are in agreement with the lack 
of significant reactivity observed by CTL clones as A75, A83, 
and A94 on most HLA-A2 §  normal and neoplastic cells of 
nonmelanocyte  antigen. 
The experiments  performed with  quiescent  melanocytes 
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antigens whose expression is not restricted to proliferating 
cells. This is true for the significant lysis seen up to 144 h 
after seeding melanocytes in conditions that completely ar- 
rest their proliferation. We cannot rule out the possibility 
that CTL-mediated recognition of the quiescent melanocytes 
may disappear after 144 h of culture in conditions of growth 
arrest. However, experiments of CTL-mediated lysis on quies- 
cent cells beyond the 144 h  limit could not be performed 
because of the death of the melanocytes when cultured in 
the basal medium for periods longer than 6 d. On the other 
hand, our data indicate that the same CTL clones that can 
recognize the HLA-A2 + melanocytes can also kill the fresh, 
uncultured autologous melanoma. This is consistent with 
the recognition of antigens expressed in vivo at least by the 
neoplastic cells. Clearly, it remains to be seen whether fresh, 
uncultured melanocytes, directly purified from patients' tissues, 
can be recognized by these CTL clones. In fact, the avail- 
ability of autologous, uncultured melanocytes would allow 
one to perform the critical experiment that may formally prove 
whether antigens recognized by T cells on melanoma are also 
expressed in vivo on normal cells of the same tissue. A finding 
ofCTL lysis on fresh uncultured melanocytes might strengthen 
the hypothesis that an immune mechanism could lead to de- 
struction of melanocytes and melanoma in vivo and might 
also be interpreted as an indication that it is possible to alter 
an existing state of tolerance to tissue-related self antigens. 
Indeed, these hypotheses are in agreement with the develop- 
ment of an unexpected form of toxicity recently described 
in a proportion of melanoma patients subjected to a protocol 
that  sequentially combined chemotherapy with  IL-2 plus 
IFN-c~ (28). In fact, those authors reported for the first time 
that a depigmentation, defined as "vitiligo-like" and surely 
resulting from melanocyte destruction, occurred in a propor- 
tion of the treated patients. More importantly, this "toxicity" 
correlated significantly with tumor regression. These results 
suggested to the authors (28) that the combination of che- 
motherapy with immunotherapy, but not each of the two 
components alone, might activate a process leading to in vivo 
destruction of normal and neoplastic cells of the melanocyte 
lineage. Thus, although the precise mechanism of melanoma 
and melanocyte destruction in vivo remains to be elucidated, 
the possibility of an immune recognition of antigens shared 
between normal and neoplastic cells of the melanocyte lin- 
eage is supported by our results. 
The findings described here add new information on the 
antigenicity of human melanoma and on the role of HLA- 
A2 molecule in the immune recognition of this tumor. In 
fact, the available data suggest that the HLA-A2 molecule 
is an immunodominant class I allele for presentation of mela- 
noma antigens to autologous cytotoxic T cells (29), and that 
common melanoma antigens can be expressed by HLA-A2- 
melanomas after transfection with HLA-A2 (30). These data 
indicated that most human melanomas are antigenic and that 
most tumors from HLA-A2 + patients may share common 
melanoma antigens seen by cytotoxic T  cells.  Our results 
confirmed the data on the existence of common melanoma 
antigens seen  in association with HLA-A2.  However, the 
findings described here suggest also that at least a proportion 
of these common antigens detected by patients' T  cells on 
the tumor are not necessarily expressed as consequence of 
neoplastic transformation, but may represent a property of 
the tissue of origin of the tumor, since cultured normal me- 
lanocytes can be recognized by the same CTL clones that 
recognize all HLA-A2 + melanomas. A possibility is that the 
origin of the antigens recognized by our CTL clones on mela- 
noma and melanocytes may be linked to the differentiation 
program of cells in the melanocyte lineage. In fact, antigens 
expressed on newborn and fetal, but not adult melanocytes, 
were found also on the subset of tumors characterized as being 
in an intermediate stage of differentiation (18). With respect 
to this classification,  it is interesting that we used neonatal 
foreskin melanocytes as targets for the screening of CTL clones. 
If antigens detected by T  cells on melanoma are associated 
to the differentiation program of melanocytes, as it happens 
for serologically defined antigens, then it is possible that the 
CTL clones described in this study are directed to antigens 
that may be differentially expressed among normal or neo- 
plastic melanocytes corresponding to distinct phases  in the 
differentiation program of this lineage. This hypothesis im- 
plies  that the heterogeneity for differentiation stage,  com- 
monly found among melanomas from different patients (18), 
should  correlate with  heterogeneity for  expression  of T 
cell-defined antigens.  Therefore not  all  HLA-A2 +  mela- 
nomas may be recognized by CTL clones such as those de- 
scribed in our study. This is in agreement with the observa- 
tion  that  one out of nine HLA-A2 + melanomas was not 
lysed by the HLA-A2-restricted CTL clones. Similar possi- 
bilities exist for the recognition of melanocytes. However, 
the issue of differential expression of tissue related antigens 
on normal melanocytes might be settled only by testing the 
CTL clones on HLA-A2 + melanocytes isolated from fetal, 
newborn, and adult skin. 
In addition, the lack of lysis seen on one (Me4855) of the 
HLA-A2 § melanomas might not be dependent on antigenic 
heterogeneity linked to the differentiation stage of the tumors. 
In fact, some patients may express rare HLA-A2 alleles that 
cannot be discriminated serologicaUy, but that are readily dis- 
tinguished by T cells (31), since the HLA-A2 subtype poly- 
morphism produces changes in the peptide-binding groove 
that can affect peptide presentation (31). Therefore, it is pos- 
sible that absence of recognition of some melanomas by the 
CTL clones described in this study is dependent on the pres- 
ence of distinct HLA-A2 subtypes in the population.  The 
answer to this possible explanation of heterogeneity in CTL- 
mediated recognition of melanomas will be obtained by ap- 
plying a recently described technique of  DNA typing for HLA- 
A2 subsets (32). 
We do not know whether all HLA-A2-restricted CTL 
clones from each patient will kill HLA-A2 + melanocytes. In 
fact, it is possible that the CTL clones detected in this study 
may represent only a fraction of the HLA-A2-restricted killers 
and that other HLA-A2-restricted CTL clones may kill the 
tumor but not HLA-matched melanocytes. Only the screening 
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Targets 
HLA-A2  mAb 
Designation  Histology  expression  to: 
CTL clones 
A75  A83  A94  119  LAK 
Me9742  Metastatic melanoma  96"  -  ~  43  s 
Me9742  CD3**  1411 
Me9742  CD3***  15 II 
Me9742  HLA-I  411 
Me9742  HLA-DR  41 
Fresh Me9742  Metastatic melanoma  96  -  13 
Me13924  Metastatic melanoma  95  31 
Me18732  Metastatic melanoma  95  33 
Me8959  Metastatic melanoma  95  34 
Me16938  Metastatic melanoma  93  59 
Me4855  Metastatic melanoma  88  4 
Me10538  Primary melanoma  95  26 
Me3046/2  Metastatic melanoma  92  65 
Me14932  Metastatic melanoma  94  27 
Me5810  Primary melanoma  98  23 
MeLatt  Metastatic melanoma  0  2 
Me1402/R  Primary melanoma  0  0 
Me4024  Metastatic melanoma  0  0 
Me665/1  Metastatic melanoma  0  0 
Me9460  Metastatic melanoma  0  0 
Me13443  Metastatic melanoma  0  0 
Me1340  Metastatic melanoma  0  0 
Me1811  Metastatic melanoma  4  1 
Me4405  Primary melanoma  0  1 
R.eca458  Renal carcinoma  82  0 
R.ecaSor  R.enal  carcinoma  93  1 
R.ecaMar  R.enal  carcinoma  17  0 
HT29  Colon carcinoma  0  0 
A431  Epidermoid carcinoma  0  0 
SKBR3  Breast carcinoma  13  0 
CALU3  Lung carcinoma  91  0 
Ovca432  Ovarian carcinoma  2  0 
SKOV3  Ovarian carcinoma  91  0 
t  . 
IGR.OV1  Ovarian carcinoma  0  0 
N592  Small cell lung carcinoma  10  0 
H446  Small cell lung carcinoma  0  0 
R.e458  Normal kidney cells  83  0 
F1338/1  Fibroblast  86  0 
F8536  Fibroblast  0  1 
F9203  Fibroblast  0  0 
F3046  Fibroblast  53  0 
61 
25tl 
2511 
_7il 
56 
27 
43 
43 
39 
68 
6 
45 
67 
5A 
35 
3 
0 
2 
10 
5 
2 
0 
4 
9 
8 
2 
4 
0 
5 
5 
2 
0 
1 
5 
2 
3 
7 
9- 
1 
2 
14 
4_!1 
14il 
13~I 
2ii 
4A 
28 
43 
3_2 
6A 
7 
30 
63 
26 
2A 
2 
0 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
I 
0 
0 
0 
0 
0 
0 
2 
0 
0 
0 
1 
0 
0 
33 
oil 
iII 
01i 
36 
0 
3 
0 
3 
3 
9- 
1 
1 
0 
0 
0 
2 
3 
4 
0 
1 
2 
5 
4 
2 
3 
0 
3 
5 
0 
0 
0 
3 
2 
0 
3 
9 
0 
1 
8 
L0 
6_22 
47 
L8 
62 
26 
44 
5A 
3_00 
55 
37 
6_6 
47 
6_22 
5A 
L9 
38 
4_99 
66 
L3 
L3 
43 
L8 
66 
67 
63 
600 
62 
52 
37 
L7 
6!1 
46 
L7 
68 
28 
67 
48 
35 
4__5 
68 
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continued Table 4.  (continued) 
Targets 
CTL clones 
HLA-A2  mAb 
Designation  Histology  expression  to:  A75  A83  A94  119  LAK 
LCL9742  EBV-transformed  B cell  95  0  2  0  0  60 
LCL10538  EBV-transformed  B cell  85  0  0  0  0  46 
LCL1811  EBV-transformed  B cell  2  0  0  0  0  37 
LCL4405  EBV-transformed  B cell  0  0  3  0  0  2_11 
Specificity  of CTL clones A75, A83, A94, and 119 from patient 9742 was tested in a 4-h slCr-release assay. LAK cells were produced as described 
in the legend to Table 2. 
* Reactivity of different cells with the mAb CRll.351  (anti-HLA-A2) is expressed as percent positive cells by cytofluorimetric  analysis. Positive 
reaction with CRll.351 was confirmed  also by the mAb anti-HLA-A2 PA2.1, BB7.2, and MA2.1. All targets in the panel are positive for HLA 
class I antigens as detected by the mAb W6/32 (10). 
* Inhibition of Me9742 lysis was performed  by preincubating the effectors  with 1 #g/ml of anti-CD3 mAb OKT3('*) or TR66(***), and prein- 
cubating the target with 1 gg/ml of W6/32 (anti-HLA-class I), or L243 (anti-HLA-DR). 
S Results are expressed as percent lysis. Underlined values represent significant values of lysis (SNK test, p  =  0.01). 
II Lysis  in the presence  of antibodies is significantly  different  from lysis of the same target in the absence of antibody  (SNK test, p z  0.01). LCL9742, 
LCL10538, LCL1811, and LCL4405 are lymphoblastoid  cell lines autologous  respectively  to the tumors Me9742, Me10538, Me1811, and Me4405. 
Re458 kidney cells and fibroblasts F3046 are autologous respectively  to the tumors Reca458 and Me3046/2. 
of a large panel of HLA-A2-restricted CTL clones for lysis 
of melanoma and melanocytes will indicate whether the HLA- 
A2 molecule is a restriction element only for antigens shared 
between melanoma and melanocytes, or also for antigens ex- 
pressed on the neoplastic cells only. 
The CTL clones with reactivity on normal melanocytes 
were found not only in PBL but also in TIL. This indicates 
that HLA-A2-restricted T cells with the ability to recognize 
normal and neoplastic cells of the melanocyte lineage are not 
confined to a single tissue but can be found either in the pe- 
ripheral circulation or the tumor site. However, the analysis 
performed by T cell clones, due to the strong selection that 
occurs during the cloning procedure, does not allow us to 
draw any conclusion on the issue of  frequency of these effectors 
either in the PBL or in the TIL populations. This issue may 
be addressed only by analysis of tile molecular structure of 
the TCK expressed by these effectors (Sensi, M., et al., manu- 
script in preparation). 
Finally,  the results of the specificity assay performed with 
CTL clone 119 indicated that HLA-A2 is not the only re- 
stricting element for recognition of TAA on tumor 9742 and 
that some of the T cell-defined antigens of this tumor may 
not be frequently shared with allogeneic cells even within 
the melanocyte lineage. This suggests that the antigenicity 
of a human melanoma, as defined by autologous cytotoxic 
T cells, may be a complex phenotype resulting not only from 
heterogeneity in the tissue distribution and molecular origin 
of the antigens, but also  from the expression on the same 
tumor of common or unique antigens, and from the pres- 
ence of distinct peptide-HLA complexes. 
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